Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001725160-24-000193
Filing Date
2024-12-19
Accepted
2024-12-19 16:01:43
Documents
14
Period of Report
2024-12-17
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K/A zntl-20241217.htm   iXBRL 8-K/A 30812
  Complete submission text file 0001725160-24-000193.txt   177169

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zntl-20241217.xsd EX-101.SCH 2039
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT zntl-20241217_def.xml EX-101.DEF 4069
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zntl-20241217_lab.xml EX-101.LAB 27067
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zntl-20241217_pre.xml EX-101.PRE 16301
16 EXTRACTED XBRL INSTANCE DOCUMENT zntl-20241217_htm.xml XML 2837
Mailing Address 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121 (858) 263-4333
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

EIN.: 823607803 | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-39263 | Film No.: 241563261
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)